Table 8 Clinical trials of PDC drugs for lung cancer treatment
From: Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
PDC drug name | Target | NCT number | Status | Study phase | Actual enrollment | Primary endpoint | Start date |
|---|---|---|---|---|---|---|---|
ZL-2306 | PARP | NCT03516084 | Terminated | III | 185 | PFS | Aug 2018 |
CYH33 | STAT3 | NCT04586335 | Recruiting | I | 350 | ORR | Sep 2020 |
CYH33 | STAT3 | NCT03544905 | Recruiting | I | 100 | MTD | Jul 2018 |
MEDI9197 | IL-17RA | NCT02556463 | Terminated | I | 53 | MTD | Oct 2018 |
BT-1718 | STn | NCT03486730 | Not recruiting | I/II | 72 | MTD | Jan 2018 |
GRN1005 | LPR1 | NCT01679743 | Withdrawn | II | 20 | Not provided | Aug 2012 |
GRN1005 | LPR1 | NCT01497665 | Terminated | II | 16 | ORR | Jan 2013 |
GRN1005 | LPR1 | NCT00539383 | Completed (NA) | I | 56 | MTD | Mar 2010 |
BT-5528 | CD13 | NCT04180371 | Recruiting | I/II | 288 | MTD | Nov 2019 |
G-202 | CD13 | NCT01056029 | Completed (NA) | I | 30 | MTD | Dec 2012 |
PEN-221 | CD13 | NCT02936323 | Completed (Positive) | I/II | 89 | MTD | Dec 2016 |
tTF–NGR | CD13 | NCT02902237 | Completed (Positive) | I | 24 | MTD | Mar 2017 |
TH1902 | SORT1 | NCT04706962 | Not recruiting | I | 70 | MTD | Mar 2021 |
CBP-1008 | Frα and TRPV6 | NCT04740398 | Recruiting | I | 143 | AEs | Mar 2019 |
CBP-1018 | PSMA and FRα | NCT04928612 | Recruiting | I | 170 | AEs | Nov 2021 |
SOR-C13 | TRPV6 | NCT01578564 | Completed (NA) | I | 23 | Plasma levels of SOR-C13 | Jul 2015 |
Paclitaxel with Poliglumex | PCSK9 | NCT00487669 | Completed (Positive) | II | 14 | ORR | Nov 2009 |
Paclitaxel with Poliglumex | PCSK9 | NCT00551733 | Terminated | III | 450 | OS | Dec 2007 |
Paclitaxel with Poliglumex | PCSK9 | NCT00352690 | Terminated | II | 10 | OS | Jun 2008 |
Paclitaxel with Poliglumex | PCSK9 | NCT00269828 | Terminated | III | 600 | OS | Dec 2005 |
EP-100 | GnRH | NCT00949559 | Completed (NA) | I | 38 | Not provided | Mar 2012 |
Lutathera | – | NCT03325816 | Completed (Positive) | I/II | 9 | MTD | Nov 2017 |
[18F]Fluciclatide | αvβ5 and αvβ3 | NCT02193672 | Withdrawn | I | 0 | Not provided | Aug 2014 |
[18F]Fluciclatide | αvβ5 and αvβ3 | NCT01176500 | Withdrawn | I/II | 0 | Safety | Nov 2011 |
[18F]RGD-K5 | – | NCT00988936 | Completed (NA) | II | 35 | Usefulness | Mar 2012 |
[18F]RGD-K5 | – | NCT00743353 | Completed (NA) | I | 16 | Not provided | Jan 2009 |